Daniel Bridges
Research Subjects
Daniel Bridges has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
Andrew Boon
Department of Physiology and Pharmacology, Wake Forest University Health Sciences, Winston-Salem, NC 27157, USA
2 shared publicationsElena Grigorenko
Department of Physiology and Pharmacology, Wake Forest University Health Sciences, Winston-Salem, NC 27157, USA
2 shared publications- Leslie Citrome
New York Medical College
2 shared publications - Robert E. Hampson
Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC, United States
2 shared publications A.S.C Rice
Pain Research, Department of Anaesthetics, Faculty of Medicine, Imperial College, Chelsea and Westminster Hospital Campus, London, UK
1 shared publicationA.S.C. Rice
Pain Research|Department of Anaesthetics|Imperial College|School of Medicine|Westminster Hospital Campus|Novartis Institute for Medical Sciences
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 1 September 2022
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 175 (9) , 1298-1304
Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update
The Good Publication Practice (GPP) guideline provides recommendations for individuals and organizations that contribute to the publication of research results sponsored or supported by pharmaceuti... These updated Good Publication Practice (GPP) guidelines include recommendations for publishing company-sponsored biomedical research. The GPP guidelines apply to peer-reviewed or peer-oriented bio...
- 1 September 2022
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 175 (9) , 1298-1304
Top Cited PapersOpen AccessGood Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update
The Good Publication Practice (GPP) guideline provides recommendations for individuals and organizations that contribute to the publication of research results sponsored or supported by pharmaceuti... These updated Good Publication Practice (GPP) guidelines include recommendations for publishing company-sponsored biomedical research. The GPP guidelines apply to peer-reviewed or peer-oriented bio...
- Top Cited PapersOpen Access
- 15 September 2015
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 163 (6) , 461-464
Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3
This updated Good Publication Practice (GPP) guideline, known as GPP3, builds on earlier versions and provides recommendations for individuals and organizations that contribute to the publication of research results sponsored or supported by pharmaceutical, medical device, diagnostics, and biotechnology companies. The recommendations are designed to help individuals and organizations maintain ethical and transparent publication practices and comply with legal and regulatory requirements. These recommendations cover publications in peer-reviewed journals and presentations (oral or poster) at scientific congresses. The International Society for Medical Publication Professionals invited more than 3000 professionals worldwide to apply for a position on the steering committee, or as a reviewer, for this guideline. The GPP2 authors reviewed all applications (n = 241) and assembled an 18-member steering committee that represented 7 countries and a diversity of publication professions and institutions. From the 174 selected reviewers, 94 sent comments on the second draft, which steering committee members incorporated after discussion and consensus. The resulting guideline includes new sections (Principles of Good Publication Practice for Company-Sponsored Medical Research, Data Sharing, Studies That Should Be Published, and Plagiarism), expands guidance on the International Committee of Medical Journal Editors' authorship criteria and common authorship issues, improves clarity on appropriate author payment and reimbursement, and expands information on the role of medical writers. By following good publication practices (including GPP3), individuals and organizations will show integrity, accountability, and responsibility for accurate, complete, and transparent reporting in their publications and presentations.
- 15 September 2015
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 163 (6) , 461-464
Top Cited PapersOpen AccessGood Publication Practice for Communicating Company-Sponsored Medical Research: GPP3
This updated Good Publication Practice (GPP) guideline, known as GPP3, builds on earlier versions and provides recommendations for individuals and organizations that contribute to the publication of research results sponsored or supported by pharmaceutical, medical device, diagnostics, and biotechnology companies. The recommendations are designed to help individuals and organizations maintain ethical and transparent publication practices and comply with legal and regulatory requirements. These recommendations cover publications in peer-reviewed journals and presentations (oral or poster) at scientific congresses. The International Society for Medical Publication Professionals invited more than 3000 professionals worldwide to apply for a position on the steering committee, or as a reviewer, for this guideline. The GPP2 authors reviewed all applications (n = 241) and assembled an 18-member steering committee that represented 7 countries and a diversity of publication professions and institutions. From the 174 selected reviewers, 94 sent comments on the second draft, which steering committee members incorporated after discussion and consensus. The resulting guideline includes new sections (Principles of Good Publication Practice for Company-Sponsored Medical Research, Data Sharing, Studies That Should Be Published, and Plagiarism), expands guidance on the International Committee of Medical Journal Editors' authorship criteria and common authorship issues, improves clarity on appropriate author payment and reimbursement, and expands information on the role of medical writers. By following good publication practices (including GPP3), individuals and organizations will show integrity, accountability, and responsibility for accurate, complete, and transparent reporting in their publications and presentations.
Good publication practice for communicating company sponsored medical research: the GPP2 guidelines
In response to changes in the environment in which authors, presenters, and other contributors work together to communicate medical research the International Society for Medical Publication Professionals has updated the good publication practice guidelines
Good publication practice for communicating company sponsored medical research: the GPP2 guidelines
In response to changes in the environment in which authors, presenters, and other contributors work together to communicate medical research the International Society for Medical Publication Professionals has updated the good publication practice guidelines
- 1 June 2005
- Published by Elsevier in Neuropharmacology
- Vol. 48 (8) , 1086-1096
Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores
- 1 June 2005
- Published by Elsevier in Neuropharmacology
- Vol. 48 (8) , 1086-1096
Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores
- 1 July 2003
- Published by Elsevier in Neuroscience
- Vol. 119 (3) , 803-812
Localisation of cannabinoid receptor 1 in rat dorsal root ganglion using in situ hybridisation and immunohistochemistry
- 1 July 2003
- Published by Elsevier in Neuroscience
- Vol. 119 (3) , 803-812
Localisation of cannabinoid receptor 1 in rat dorsal root ganglion using in situ hybridisation and immunohistochemistry
- 1 December 2002
- Published by Elsevier in Chemistry and Physics of Lipids
- Vol. 121 (1-2) , 257-266
Assessment of cannabinoid induced gene changes: tolerance and neuroprotection
- 1 December 2002
- Published by Elsevier in Chemistry and Physics of Lipids
- Vol. 121 (1-2) , 257-266
Assessment of cannabinoid induced gene changes: tolerance and neuroprotection
- Top Cited Papers
- 1 July 2001
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 87 (1) , 12-26
Mechanisms of neuropathic pain
Neuropathic pain is defined as 'pain initiated or caused by a primary lesion or dysfunction in the nervous system'.94 The spectrum of neuropathic pain covers a variety of disease states (Table 1) and presents in the clinic with a variety of symptoms.145 Neuropathic pain is often reported as having a lancinating or continuous burning character and is often associated with the appearance of abnormal sensory signs, such as allodynia (pain as a result of a stimulus which does not normally provoke pain) or hyperalgesia (an increased response to a stimulus which is normally painful) (Figure 1). The sensory phenomena can be further characterized into static or dynamic sub-types. The mechanistic implication of allodynia is that elements of the sensory nervous system, which normally signal innocuous sensation have begun to encode painful stimuli, whilst in hyperalgesia the structures that sub-serve nociception have become hyperexcitable. Neuropathic pain is an area of largely unmet therapeutic need. The current pharmacological mainstays of clinical management are tricyclic anti-depressants and certain anti- convulsants,92 119 but these only achieve clinically signifi- cant (greater than 50%) pain relief in less than 50% of patients and are associated with sub-optimal side effect profiles. Opioids are generally considered to be less effective in neuropathic pain than in inflammatory pain, with the dose response curve of opioids in neuropathic pain shifted to the right of that for inflammatory pain, although the extent of this difference is controversial.112 The majority of research into neuropathic pain mechan- isms has concentrated on changes in the peripheral nerve or spinal cord after peripheral nerve injury and, therefore, most available evidence relates to changes in these parts of the nervous system and the review will, therefore, focus on these aspects. Nevertheless, it is important to recognize that alterations in the brain have also been demonstrated following peripheral nerve injury, but much less is known about the significance of these changes. For example, phantom limb pain has been shown to be associated with re- organization of the cortex of humans.43 The degree of cortical re-organization, as determined by BTi neuro- magnetic imaging, was linked in a linear fashion to the intensity of pain, with an increase in re-organization being associated with greater pain intensity.43 A more recent study indicated that cortical re-organization was evident only in patients with phantom limb pain, and not in patients with non-painful phantom limb phenomena or congenital absence of the limb.44
- 1 July 2001
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 87 (1) , 12-26
Top Cited PapersMechanisms of neuropathic pain
Neuropathic pain is defined as 'pain initiated or caused by a primary lesion or dysfunction in the nervous system'.94 The spectrum of neuropathic pain covers a variety of disease states (Table 1) and presents in the clinic with a variety of symptoms.145 Neuropathic pain is often reported as having a lancinating or continuous burning character and is often associated with the appearance of abnormal sensory signs, such as allodynia (pain as a result of a stimulus which does not normally provoke pain) or hyperalgesia (an increased response to a stimulus which is normally painful) (Figure 1). The sensory phenomena can be further characterized into static or dynamic sub-types. The mechanistic implication of allodynia is that elements of the sensory nervous system, which normally signal innocuous sensation have begun to encode painful stimuli, whilst in hyperalgesia the structures that sub-serve nociception have become hyperexcitable. Neuropathic pain is an area of largely unmet therapeutic need. The current pharmacological mainstays of clinical management are tricyclic anti-depressants and certain anti- convulsants,92 119 but these only achieve clinically signifi- cant (greater than 50%) pain relief in less than 50% of patients and are associated with sub-optimal side effect profiles. Opioids are generally considered to be less effective in neuropathic pain than in inflammatory pain, with the dose response curve of opioids in neuropathic pain shifted to the right of that for inflammatory pain, although the extent of this difference is controversial.112 The majority of research into neuropathic pain mechan- isms has concentrated on changes in the peripheral nerve or spinal cord after peripheral nerve injury and, therefore, most available evidence relates to changes in these parts of the nervous system and the review will, therefore, focus on these aspects. Nevertheless, it is important to recognize that alterations in the brain have also been demonstrated following peripheral nerve injury, but much less is known about the significance of these changes. For example, phantom limb pain has been shown to be associated with re- organization of the cortex of humans.43 The degree of cortical re-organization, as determined by BTi neuro- magnetic imaging, was linked in a linear fashion to the intensity of pain, with an increase in re-organization being associated with greater pain intensity.43 A more recent study indicated that cortical re-organization was evident only in patients with phantom limb pain, and not in patients with non-painful phantom limb phenomena or congenital absence of the limb.44
- Open Access
- 1 June 2001
- Published by Wiley in British Journal of Pharmacology
- Vol. 133 (4) , 586-594
The synthetic cannabinoid WIN55,212‐2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain
The analgesic properties of the synthetic cannabinoid WIN55,212‐2 were investigated in a model of neuropathic pain. In male Wistar rats, bilateral hind limb withdrawal thresholds to cold, mechanical and noxious thermal stimuli were measured. Following this, unilateral L5 spinal nerve ligation was performed. Seven days later, sensory thresholds were reassessed and the development of allodynia to cold and mechanical stimuli and hyperalgesia to a noxious thermal stimulus confirmed. The effect of WIN55,212‐2 (0.1 – 5.0 mg kg−1, i.p.) on the signs of neuropathy was then determined; there was a dose related reversal of all three signs of painful neuropathy at doses which did not generally alter sensory thresholds in the contralateral unligated limb. This effect was prevented by co‐administration of the CB1 receptor antagonist SR141716a, but not by co‐administration of the CB2 receptor antagonist SR144528, suggesting this action of WIN55,212‐2 is mediated via the CB1 receptor. Administration of SR141716a alone had no affect on the observed allodynia and hyperalgesia, which does not support the concept of an endogenous analgesic tone. These data indicate that cannabinoids may have therapeutic potential in neuropathic pain, and that this effect is mediated through the CB1 receptor. British Journal of Pharmacology (2001) 133, 586–594; doi:10.1038/sj.bjp.0704110
- 1 June 2001
- Published by Wiley in British Journal of Pharmacology
- Vol. 133 (4) , 586-594
Open AccessThe synthetic cannabinoid WIN55,212‐2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain
The analgesic properties of the synthetic cannabinoid WIN55,212‐2 were investigated in a model of neuropathic pain. In male Wistar rats, bilateral hind limb withdrawal thresholds to cold, mechanical and noxious thermal stimuli were measured. Following this, unilateral L5 spinal nerve ligation was performed. Seven days later, sensory thresholds were reassessed and the development of allodynia to cold and mechanical stimuli and hyperalgesia to a noxious thermal stimulus confirmed. The effect of WIN55,212‐2 (0.1 – 5.0 mg kg−1, i.p.) on the signs of neuropathy was then determined; there was a dose related reversal of all three signs of painful neuropathy at doses which did not generally alter sensory thresholds in the contralateral unligated limb. This effect was prevented by co‐administration of the CB1 receptor antagonist SR141716a, but not by co‐administration of the CB2 receptor antagonist SR144528, suggesting this action of WIN55,212‐2 is mediated via the CB1 receptor. Administration of SR141716a alone had no affect on the observed allodynia and hyperalgesia, which does not support the concept of an endogenous analgesic tone. These data indicate that cannabinoids may have therapeutic potential in neuropathic pain, and that this effect is mediated through the CB1 receptor. British Journal of Pharmacology (2001) 133, 586–594; doi:10.1038/sj.bjp.0704110